ABSTRACT
In view of the lack of curative treatments, high-dose myelo/ immunosuppression with autologous stem cell transplantation (HSCT) has been utilized as therapy of multiple sclerosis (MS). HSCT has immunosuppressive and immunomodulatory effects which may tip the immunological balance towards disease quiescense. Does support for this hypothesis exist from current animal and human trials and if so, what information do they tell us in design of a future trial?
